Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

HIV Clinical Trial

Official title:

A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02475629
• Other study ID #: TMB-301
• Status: Completed
• Phase: Phase 3
• Start date: August 2015
• Est. completion date: December 2016

Study information

• Verified date: February 2020
• Source: TaiMed Biologics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.

Description:

This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1. Patients must have been treated with HAART for at least 6 months and be failing or have recently failed (i.e., in the last 8 weeks) therapy to determine baseline viral load.

Days 0-6 of the study will be a "control period." During Days 0 through 6 patients will be monitored on current failing therapy (or no therapy, if the patient has failed and discontinued treatment within the 8 weeks preceding Screening).

Days 7-13 of the study will be an "essential monotherapy period." During Days 7 through 13 patients will continue on current failing therapy and receive one 2000 mg dose (loading dose) of ibalizumab on Day 7. Day 7 is Baseline for the treatment period (Day 7-Week 25).

Day 14-Week 25 of the study will be the "maintenance period." On Day 14 (primary endpoint), the OBR will be initiated and must include at least one agent to which the patient's virus is susceptible. Beginning at Day 21, 800 mg of ibalizumab will be administered every 2 weeks through Week 23.

End of Study evaluations will be performed at Week 25, and a follow-up visit will be conducted at Week 29.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Are capable of understanding and have voluntarily signed the informed consent document

• Have documented HIV-1 infection by official, signed, written history (e.g., laboratory report), otherwise an HIV-antibody test will be performed

• Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before Screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV

• Are able and willing to comply with all protocol requirements and procedures

• Have a life expectancy that is >6 months.

• Have a viral load >1,000 copies/mL and documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications as measured by resistance testing

• Have a history of at least 6 months on antiretroviral treatment

• Are receiving a stable highly active antiretroviral regimen for at least 8 weeks before Screening and are willing to continue that regimen until Day 14, OR (in the past 8 weeks) have failed and are off therapy and are willing to stay off therapy until Day 14

• Have full viral sensitivity/susceptibility to at least one antiretroviral agent, other than ibalizumab, as determined by the screening resistance tests and be willing and able to be treated with at least one agent to which the patient's viral isolate is fully sensitive/susceptible according to the screening resistance tests as a component of OBR

• If sexually active, are willing to use an effective method of contraception during the study and for 30 days after the last administration of the study drug

Exclusion Criteria:

• Any active AIDS-defining illness per Category C conditions according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection, with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to HIV

• Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study

• Any significant acute illness within 1 week before the initial administration of study drug

• Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.

• Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 12 weeks before Enrollment

• Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)

• Any vaccination within 7 days before Enrollment

• Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding

• Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations

• Any previous clinically significant allergy or hypersensitivity to any excipient in the ibalizumab formulation

• Any radiation therapy during the 28 days before first administration of investigational medication

• Any Grade 3 or 4 laboratory abnormality according to the Division of AIDS grading scale, except for the following asymptomatic Grade 3 events triglyceride elevation total cholesterol elevation

Related Conditions & MeSH terms

• HIV

Intervention

Biological:
• ibalizumab
2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks

Drug:
• Optimized Background Regimen (OBR)
All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.

Locations

Country	Name	City	State
Puerto Rico	Clinical Research PR, Inc	San Juan
Taiwan	E-Da Hospital	Kaohsiung
Taiwan	National Taiwan University Hospital	Taipei
United States	AIDS Research Consortium of Atlanta	Atlanta	Georgia
United States	University of Maryland, Institute of Human Virology	Baltimore	Maryland
United States	Montefiore Medical Center	Bronx	New York
United States	Carolinas HealthCare System	Charlotte	North Carolina
United States	North Texas Infectious Disease Consultants	Dallas	Texas
United States	Henry Ford Health Systems	Detroit	Michigan
United States	Gary Richmond, MD, PA	Fort Lauderdale	Florida
United States	Midway Immunology and Research Center	Fort Pierce	Florida
United States	Research Access Network	Houston	Texas
United States	Long Beach Education and Research Consultants	Long Beach	California
United States	AIDS Healthcare Foundation	Los Angeles	California
United States	Anthony Mills, MD, Inc.	Los Angeles	California
United States	Charles R. Drew Univ. of Med. & Science Clinical and Translational Research Center	Los Angeles	California
United States	Ruane Medical and Clinical Research Institute	Los Angeles	California
United States	Southern California Permanente Medical Group	Los Angeles	California
United States	W King Health Care Group	Los Angeles	California
United States	University of Miami	Miami	Florida
United States	Yale University	New Haven	Connecticut
United States	ACRIA	New York	New York
United States	Circle Care Center, LLC	Norwalk	Connecticut
United States	Orlando Immunology Center	Orlando	Florida
United States	Palmtree Clinical Research Inc.	Palm Springs	California
United States	Kaiser Foundation Research Institute	San Francisco	California
United States	Quest Clinical Research	San Francisco	California
United States	St. John Hospital and Medical Center	Southfield	Michigan
United States	Georgetown University School of Medicine	Washington	District of Columbia
United States	Triple O Research Institute	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
TaiMed Biologics Inc.

Countries where clinical trial is conducted

United States,  Puerto Rico,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacodynamics: CD4 Receptor Occupancy	% of CD receptors occupied by ibalizumab on CD4+ T-cells	At Week 25/End of Study
Primary	Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF	Proportion of participants (%) achieving a viral load reduction of at least 0.5 log from baseline (Day 7)	Day 14
Primary	Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol Correct	Proportion of patients (%) with a viral load decrease of at least 0.5 log 10 from baseline (day 7)	Day 14
Secondary	Efficacy: Proportion of Patients With Undetectable Viral Load: ITT-MEF	Proportion of patients with undetectable Viral Load (<50 copies/mL, and <400 copies/mL)	Week 25 /end of study
Secondary	Efficacy: Proportion of Patients With Undetectable HIV-RNA Levels: Protocol Correct	Proportion of patients (%) with HIV-RNA levels < 50 copies/mL and < 400 copies/mL at Week 25/End of Study	Week 25/End of Study
Secondary	Mean Change in Viral Load as a Measure of Efficacy - ITT-MEF	Mean change from Day 7/Baseline in log 10 vial load measured at Day 14	Day 7 and Day 14
Secondary	Mean Change in Viral Load as a Measure of Efficacy - Protocol Correct	Mean change from Day 7/Baseline in Log 10 viral load measured at Day 14	Day 7 and Day 14
Secondary	End of Study Viral Load Reductions as a Measure of Efficacy - Intent to Treat Analysis	Proportion of patients achieving a >/= 0.5 log10 and >/= 1.0 log10 decrease from Day 7/Baseline in viral load at Week 25/End of Study	at Week 25/End of Study
Secondary	End of Study Viral Load Reductions as a Measure of Efficacy - Protocol Correct Analysis	Proportion of patients achieving a >/= 0.5 log10 and >/= 1.0 log10 decrease from Day 7/Baseline in viral load at Week 25/End of Study	at Week 25/End of Study
Secondary	Mean Change in CD4+ Cell Count as a Measure of Efficacy and Safety - ITT	Mean change from Day 7/Baseline in CD4+ cell count at Week 25/End of Study	Day 7 and Week 25/End of Study
Secondary	Mean Change in CD4+ Cell Count as a Measure of Efficacy and Safety - Protocol Correct	Mean change from Day 7/Baseline in CD4+ cell count at Week 25/End of Study	Day 7 and Week 25/End of Study
Secondary	Safety: Proportion of Participants Experiencing Adverse Events	Proportion of participants experiencing at least one treatment emergent adverse event to week 25/End of Study	Through Week 25/End of Study
Secondary	Proportion of Participants Experiencing Adverse Event Related to Study Drug as a Measure of Safety and Tolerability	Proportion of participants experiencing a treatment emergent adverse event determined by the investigator to be related to study drug	Through Week 25/End of Study
Secondary	Proportion of Participants Experiencing Serious Adverse Event as a Measure of Safety and Tolerability	Proportion of participants experiencing at least one serious treatment emergent adverse event, excluding death	Through Week 25/End of Study
Secondary	Proportion of Participants Discontinuing Study Drug Due to Adverse Event	Proportion of participants discontinuing study drug due to occurrence of treatment emergent adverse event	Through Week 25/End of Study
Secondary	Proportion of Participants Experiencing Adverse Event Grade 3 and Higher as a Measure of Safety and Tolerability	Proportion of participants experiencing treatment emergent adverse event Grade 3 and higher	Through Week 25/End of Study
Secondary	Proportion of Participants Experiencing Adverse Event With Death as Outcome as a Measure of Safety and Tolerability	Proportion of participants experiencing treatment emergent adverse event with death as the outcome, regardless of relationship to study drug	Through Week 25/End of Study
Secondary	Proportion of Participants Experiencing New AIDS-defining Adverse Event According to CDC Criteria as a Measure of Safety and Tolerability	Proportion of participants experiencing treatment emergent adverse event that is AIDS-defining by the CDC adverse event classification criteria for HIV infection	Through Week 25/End of Study